News
TXMD
2.110
+3.94%
0.080
Weekly Report: what happened at TXMD last week (0615-0619)?
Weekly Report · 6d ago
TherapeuticsMD Inc. Stock Slides 14.1%, Underperforms Market
Dow Jones · 06/18 20:32
Weekly Report: what happened at TXMD last week (0608-0612)?
Weekly Report · 06/15 10:09
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
NASDAQ · 06/15 02:02
TherapeuticsMD Inc. Stock Advances 20.9%, Outperforms Market
Dow Jones · 06/12 20:32
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 06/12 17:05
TherapeuticsMD Inc. Stock Sheds 5.5%, Underperforms Market
Dow Jones · 06/08 20:34
Weekly Report: what happened at TXMD last week (0601-0605)?
Weekly Report · 06/08 10:06
Weekly Report: what happened at TXMD last week (0525-0529)?
Weekly Report · 06/01 10:09
Weekly Report: what happened at TXMD last week (0518-0522)?
Weekly Report · 05/25 10:12
Weekly Report: what happened at TXMD last week (0511-0515)?
Weekly Report · 05/18 10:12
TherapeuticsMD Says Company Continues To Evaluate Strategic Alternatives, Including Acquisition Or Merger
Benzinga · 05/12 21:47
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives
TipRanks · 05/12 20:47
Therapeutics MD reports Q1 results
Seeking Alpha · 05/12 20:24
TherapeuticsMD swings to Q1 net income as license revenue rises
Reuters · 05/12 20:13
TherapeuticsMD swings to FY26 Q1 profit of $103,000; revenue rises 84.2% to $724,000
PUBT · 05/12 20:08
THERAPEUTICSMD INC - COMPANY CONTINUES TO EVALUATE STRATEGIC ALTERNATIVES INCLUDING ACQUISITION OR MERGER
Reuters · 05/12 20:05
TherapeuticsMD: Q1 Earnings Snapshot
Barchart · 05/12 15:51
Weekly Report: what happened at TXMD last week (0504-0508)?
Weekly Report · 05/11 10:10
Weekly Report: what happened at TXMD last week (0427-0501)?
Weekly Report · 05/04 10:08
More
Webull provides a variety of real-time TXMD stock news. You can receive the latest news about Therapeuticsmd Inc through multiple platforms. This information may help you make smarter investment decisions.
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).